Skip to main content

Table 1 Schedule of assessments

From: Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial

  Screening Randomization 3 monthly
FU
6 monthly
FU
End of study
25(OH)D3 serum levels   X X
(when 25(OH)D3 levels >80 ng/ml and study drug temporarily interrupted)
X  
Blood sample for DNA analysis   X    
Hemoglobin, Hematocrit X     X
WBC count and differentiation X    X X
RBC count X     X
Platelet count X     X
Renal function (creatinine) X     X
Liver function (AF, ALT, gamma-GT, LDH) X     X
Serum calcium X   X   X
Serum phosphate X   X   X
Albumin X     X
24 h urine calcium      X